Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2019
Price : $35 *
At a glance
- Drugs Ticagrelor (Primary) ; Prasugrel
- Indications Acute coronary syndromes; Thrombosis
- Focus Therapeutic Use
- Acronyms ISAR-REACT5
- 01 Sep 2019 Results published in the New England Journal of Medicine
- 13 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jul 2019.
- 08 May 2019 Planned End Date changed from 1 Jan 2021 to 1 Jun 2021.